Cordis to present Cypher studies

Cordis Corporation has announced that it will present clinical data that will highlight the benefits of the Cypher Sirolimus-eluting Coronary Stent.

The Johnson & Johnson company will also deliver clinical data and professional education opportunities on other parts of its peripheral vascular group product range.

The presentations will take place at the annual Transcatheter Cardiovascular Therapeutics 2007 meeting (TCT 2007), to be held in Washington DC from October 20th to 25th.

David E Kandzari, chief medical officer at Cordis, indicated that the studies set to be presented would continue to add to the extensive body of evidence associated with the Cypher stent and its other products.

“The studies and presentations will further validate the clinical advantages of drug-eluting stents compared with bare metal stents, highlight economic data of stenting versus surgery and feature the clinical benefits of the Cypher stent versus the Taxus stent.”

The Cypher stent is currently available in more than 80 countries and has been used in the treatment of over three million patients with coronary artery disease.

Earlier this year Cordis demonstrated that the Cypher stent outperformed the Taxus stent when used in small coronary vessels following the release of clinical data published in the Journal of the American College of Cardiology.